CureVac (NASDAQ:CVAC) Shares Up 5%

CureVac (NASDAQ:CVAC)’s stock price rose 5% during mid-day trading on Monday . The company traded as high as $3.57 and last traded at $3.57. Approximately 60,733 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 987,263 shares. The stock had previously closed at $3.40.

Analyst Ratings Changes

A number of research firms have recently commented on CVAC. Guggenheim restated a “neutral” rating on shares of CureVac in a report on Friday, April 5th. Leerink Partnrs downgraded CureVac from an “outperform” rating to a “market perform” rating in a report on Thursday, April 25th. Finally, SVB Leerink downgraded CureVac from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $12.00 to $4.00 in a report on Thursday, April 25th.

CureVac Trading Up 0.3 %

The company has a current ratio of 2.25, a quick ratio of 2.09 and a debt-to-equity ratio of 0.08. The firm has a fifty day moving average of $3.44 and a 200 day moving average of $3.46.

CureVac (NASDAQ:CVAC) last announced its earnings results on Thursday, May 23rd. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.12). CureVac had a negative net margin of 463.49% and a negative return on equity of 49.22%. The company had revenue of $13.43 million for the quarter, compared to analysts’ expectations of $14.51 million. On average, equities analysts forecast that CureVac will post -1.11 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG raised its stake in CureVac by 5.1% during the 3rd quarter. Deutsche Bank AG now owns 72,510 shares of the company’s stock valued at $495,000 after acquiring an additional 3,491 shares in the last quarter. Federated Hermes Inc. raised its stake in shares of CureVac by 33.3% in the 3rd quarter. Federated Hermes Inc. now owns 40,000 shares of the company’s stock worth $273,000 after buying an additional 10,000 shares in the last quarter. Vontobel Holding Ltd. acquired a new stake in shares of CureVac in the fourth quarter valued at $45,000. Ballentine Partners LLC acquired a new position in CureVac during the first quarter worth about $38,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its position in CureVac by 45.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 44,122 shares of the company’s stock worth $184,000 after acquiring an additional 13,687 shares in the last quarter. Institutional investors and hedge funds own 17.26% of the company’s stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.